Volume 176 - Issue 10

Is subcutaneous or intramuscular naloxone as effective as intravenous naloxone in the treatment of life-threatening heroin overdose?

Authors:  Jason Wasiak and Ornella Clavisi

Med J Aust 2002; 176 (10): 495. || doi: 10.5694/j.1326-5377.2002.tb04524.x
Published online: 20 May 2002
Summary of findings

In a comparative study using historical controls, Wagner et al1 compared naloxone administered intravenously or subcutaneously to patients in the community with suspected opioid overdose. The two intervention arms were 0.4 mg IV naloxone and 0.8 mg SC naloxone.

The study was conducted sequentially in two phases: the IV phase, from 1 June to 30 June 1996, and the SC phase, from 1 July to 1 September 1996. Ambulance attendants in a regional district of British Columbia, Canada, administered naloxone to people meeting the British Columbia Ambulance Services' criteria for suspected overdose (ie, reduced consciousness, history suggestive of opioid use, and respiratory rate of less than 10 breaths per minute). The protocol also included a second dose of SC or IV naloxone if the first dose was not observed to be physiologically effective.

The primary outcomes of interest included the time interval from arrival at the patient's side until the respiratory rate rose above 10 breaths per minute, the time interval from arrival at patient's side to naloxone administration, and the duration of bag–valve–mask ventilation. Overall, there was no significant difference between the two modes of naloxone administration with regard to the time interval between arrival at the patient's side and attainment of a respiratory rate greater than 10 breaths per minute (9.3 ± 4.2 minutes [IV] v 9.6 ± 4.6 min [SC]; P = 0.67). There was also no significant difference in duration of respiratory bag–valve–mask ventilation between administration arms (8.1 ± 6.0 minutes [IV] v 9.1 ± 4.8 minutes [SC]; P = 0.20; 95% CI of difference, –2.53 to 0.53).